Ten-Patient Trial: Remarkable Responses in Pediatric Cancers

A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of ge...

Descripción completa

Detalles Bibliográficos
Autor principal: Mardis, Elaine R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
CCR Translations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690083/
https://www.ncbi.nlm.nih.gov/pubmed/37733329
http://dx.doi.org/10.1158/1078-0432.CCR-23-2232
_version_ 1785152486897614848
author Mardis, Elaine R.
author_facet Mardis, Elaine R.
author_sort Mardis, Elaine R.
collection PubMed
description A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair–based susceptibility. See related article by Das et al., p. 4770
format Online
Article
Text
id pubmed-10690083
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for Cancer Research
record_format MEDLINE/PubMed
spelling pubmed-106900832023-12-02 Ten-Patient Trial: Remarkable Responses in Pediatric Cancers Mardis, Elaine R. Clin Cancer Res CCR Translations A clinical trial of nivolumab in 10 patients with pediatric cancer with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation–burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair–based susceptibility. See related article by Das et al., p. 4770 American Association for Cancer Research 2023-12-01 2023-09-21 /pmc/articles/PMC10690083/ /pubmed/37733329 http://dx.doi.org/10.1158/1078-0432.CCR-23-2232 Text en ©2023 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.
spellingShingle CCR Translations
Mardis, Elaine R.
Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title_full Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title_fullStr Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title_full_unstemmed Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title_short Ten-Patient Trial: Remarkable Responses in Pediatric Cancers
title_sort ten-patient trial: remarkable responses in pediatric cancers
topic CCR Translations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690083/
https://www.ncbi.nlm.nih.gov/pubmed/37733329
http://dx.doi.org/10.1158/1078-0432.CCR-23-2232
work_keys_str_mv AT mardiselainer tenpatienttrialremarkableresponsesinpediatriccancers

Ejemplares similares